Antibodies binding to vista at acidic pH

US12091462B2 · kind B2 · utility

Assignees

• Five Prime Therapeutics, Inc. · US
• Bristol-Myers Squibb Company · US

Inventors

• Robert J. Johnston · San Mateo, US
• Arvind Rajpal · San Francisco, US
• Paul O. Sheppard · Granite Falls, US
• Luis Borges · Seattle, US
• Andrew Rankin · Redwood City, US
• Keith Sadoon Bahjat · Portland, US
• Alan J. Korman · Piedmont, US
• Xiaodi Deng · San Mateo, US
• Lin Hui Su · Somerville, US
• Ginger Rakestraw · Cambridge, US
• Jason Robert Pinckney · Westborough, US
• David A. Critton · Pennington, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Ekaterina Deyanova · Lawrenceville, US
• Michael Quigley · Keyano, CA
• Hadia Lemar · Tracy, US
• Akbar Nayeem · Newtown, US

Key dates

• Filing date: Jul 10, 2019
• Grant date: Sep 17, 2024
• Expiry date: Dec 12, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.